Reversal of renal dysfunction by targeted administration of VEGF into the stenotic kidney: a novel potential therapeutic approach
- 15 May 2012
- journal article
- Published by American Physiological Society in American Journal of Physiology-Renal Physiology
- Vol. 302 (10) , F1342-F1350
Abstract
Renal microvascular (MV) damage and loss contribute to the progression of renal injury in renovascular disease (RVD). Whether a targeted intervention in renal microcirculation could reverse renal damage is unknown. We hypothesized that intrarenal vascular endothelial growth factor (VEGF) therapy will reverse renal dysfunction and decrease renal injury in experimental RVD. Unilateral renal artery stenosis (RAS) was induced in 14 pigs, as a surrogate of chronic RVD. Six weeks later, renal blood flow (RBF) and glomerular filtration rate (GFR) were quantified in vivo in the stenotic kidney using multidetector computed tomography (CT). Then, intrarenal rhVEGF-165 or vehicle was randomly administered into the stenotic kidneys (n = 7/group), they were observed for 4 additional wk, in vivo studies were repeated, and then renal MV density was quantified by 3D micro-CT, and expression of angiogenic factors and fibrosis was determined. RBF and GFR, MV density, and renal expression of VEGF and downstream mediators such as p-ERK 1/2, Akt, and eNOS were significantly reduced after 6 and at 10 wk of untreated RAS compared with normal controls. Remarkably, administration of VEGF at 6 wk normalized RBF (from 393.6 ± 50.3 to 607.0 ± 45.33 ml/min, P < 0.05 vs. RAS) and GFR (from 43.4 ± 3.4 to 66.6 ± 10.3 ml/min, P < 0.05 vs. RAS) at 10 wk, accompanied by increased angiogenic signaling, augmented renal MV density, and attenuated renal scarring. This study shows promising therapeutic effects of a targeted renal intervention, using an established clinically relevant large-animal model of chronic RAS. It also implies that disruption of renal MV integrity and function plays a pivotal role in the progression of renal injury in the stenotic kidney. Furthermore, it shows a high level of plasticity of renal microvessels to a single-dose VEGF-targeted intervention after established renal injury, supporting promising renoprotective effects of a novel potential therapeutic intervention to treat chronic RVD.Keywords
This publication has 33 references indexed in Scilit:
- Early Loss of Peritubular Capillaries after Kidney TransplantationJournal of the American Society of Nephrology, 2011
- Grb-2–associated binder 1 (Gab1) regulates postnatal ischemic and VEGF-induced angiogenesis through the protein kinase A–endothelial NOS pathwayProceedings of the National Academy of Sciences, 2011
- Renal Microvascular Disease Determines the Responses to Revascularization in Experimental Renovascular DiseaseCirculation: Cardiovascular Interventions, 2010
- Role of renal microcirculation in experimental renovascular diseaseNephrology Dialysis Transplantation, 2009
- Intramuscular VEGF repairs the failing heart: role of host-derived growth factors and mobilization of progenitor cellsAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2009
- VEGF-A Stimulates ADAM17-Dependent Shedding of VEGFR2 and Crosstalk Between VEGFR2 and ERK SignalingCirculation Research, 2008
- Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healingAngiogenesis, 2008
- MAPK/ERK signalling mediates VEGF‐induced bone marrow stem cell differentiation into endothelial cellJournal of Cellular and Molecular Medicine, 2008
- Letter To The Editor: “Renal Microvascular Abnormality in Chronic Kidney Disease”Renal Failure, 2006
- Cortical Microvascular Remodeling in the Stenotic KidneyArteriosclerosis, Thrombosis, and Vascular Biology, 2004